Novel Autoantibodies in Rheumatoid Arthritis: Translational Prospects from Seronegative Breakthrough to Precision Diagnosis and Treatment
Inflammation · 05.08.2026 · 49 (1)
DOI: 10.1007/s10753-026-02567-7 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Inflammation, online erschienen am 05.08.2026. Verfasst von Zewen Wu und 6 weiteren Autor:innen. Beteiligte Einrichtung: Third Hospital of Shanxi Medical University, Shanxi Bethune Hospital, Shanxi Academy of Medical Sciences, Tongji Shanxi Hospital, Taiyuan, 030032, Ch…. Hauptthemen laut MEDLINE: Arthritis, Rheumatoid, Autoantibodies, Precision Medicine. Die Arbeit nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: the Shanxi Provincial Health Commission Research Project, Research and Innovation Team Project for Scientific Breakthroughs at Shanxi Bethune Hospital.
Abstract (Originalsprache)
Rheumatoid Arthritis (RA) is an autoimmune disease characterized by chronic, erosive synovitis. While significant progress and breakthroughs have been made in disease diagnosis through basic research and clinical practice, approximately 30%–40% of seronegative RA patients still experience diagnostic delays and fail to achieve treatment targets. In recent years, the discovery of novel autoantibodies and biomarkers has opened new avenues for addressing this challenge. These molecules target post-translationally modified (PTM) antigens other than citrullinated proteins, while some are recognized independently of PTMs. They are also linked to key pathological processes such as inflammation, metabolism, and signal transduction. Experimental and clinical evidence directly or indirectly supports their regulatory roles in these processes. This review systematically summarizes the discovery process, target antigen functions, diagnostic efficacy, and roles in the pathogenesis of these novel antibodies. It focuses on their significant potential to improve the diagnosis rate of seronegative RA, predict disease progression and bone erosion risk, as well as define new disease subtypes. However, the precise mechanisms by which these autoantibodies contribute to RA pathogenesis remain to be fully elucidated. Furthermore, this article discusses current challenges, including detection standardization and clinical validation, and offers an outlook on the prospects for precision diagnosis and personalized treatment based on multi-autoantibody panels.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Third Hospital of Shanxi Medical University, Shanxi Bethune Hospital, Shanxi Academy of Medical Sciences, Tongji Shanxi Hospital, Taiyuan, 030032, China.
- Brigham and Women's Hospital, Harvard Medical School, Boston, MA, 02115, USA.
- Third Hospital of Shanxi Medical University, Shanxi Bethune Hospital, Shanxi Academy of Medical Sciences, Tongji Shanxi Hospital, Taiyuan, 030032, China. zhangly@sxbqeh.com.cn.
Förderung
- the Shanxi Provincial Health Commission Research Project
- Research and Innovation Team Project for Scientific Breakthroughs at Shanxi Bethune Hospital
Zitieren
APA
Wu, Z., Zhang, H., Zhang, J., Gong, X., Jia, Z., Gao, C., & Zhang, L. (2026). Novel Autoantibodies in Rheumatoid Arthritis: Translational Prospects from Seronegative Breakthrough to Precision Diagnosis and Treatment. Inflammation, 49(1). https://doi.org/10.1007/s10753-026-02567-7
Vancouver
Wu Z, Zhang H, Zhang J, Gong X, Jia Z, Gao C, et al. Novel Autoantibodies in Rheumatoid Arthritis: Translational Prospects from Seronegative Breakthrough to Precision Diagnosis and Treatment. Inflammation. 2026;49(1). doi:10.1007/s10753-026-02567-7
BibTeX
@article{Wu2026,
author = {Wu, Zewen and Zhang, Huijing and Zhang, Jiapeng and Gong, Xueyan and Jia, Zhen and Gao, Chong and Zhang, Liyun},
title = {Novel Autoantibodies in Rheumatoid Arthritis: Translational Prospects from Seronegative Breakthrough to Precision Diagnosis and Treatment},
journal = {Inflammation},
year = {2026},
volume = {49},
number = {1},
doi = {10.1007/s10753-026-02567-7}
}
EUVIMED